Skip to main content
OpenTrials
Completed

NCT Number: NCT06215859

Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Herniorrhaphy

MR-107A-02 is being studied to investigate its efficacy and safety for treatment of acute pain after herniorrhaphy.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Investigator site 210, Sheffield, Alabama, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Main Inclusion Criteria:

  • Requirement for unilateral open inguinal herniorrhaphy with mesh under general anesthesia.
  • Has an American Society of Anesthesiologists Physical Status of I, II, or III.
  • Pain Intensity (PI) using NRS-R ≥4 at any given timepoint during the 5 hours following end of surgery in the eligibility assessment as well as in the baseline assessment (NRS-R and NRS-A) immediately pre-dosing.
  • Rating of moderate or severe pain on a 4-point categorical pain rating scale (i.e., none, mild, moderate, severe) during the 5 hours following end of surgery.
  • Able to understand and complete the study requirements (including literacy, to enable diary and questionnaire completion), provide written informed consent, and agree to abide by the study protocol and its restrictions.

Main Exclusion Criteria:

  • Previously dosed with this formulation of MR 107A 02.
  • Had any prior inguinal hernia repair in the past 24 months.
  • Has a planned concurrent surgical procedure (e.g., bilateral herniorrhaphy).
  • Has a pre-existing concurrent acute or chronic painful physical/restrictive condition expected to require analgesic treatment in the postoperative period for pain that is not strictly related to the herniorrhaphy, and which may confound the postoperative assessments.
  • Known hypersensitivity to aspirin, NSAIDs, or other medication used in the study.
  • Body mass index (BMI) >40 kg/m2 at screening.
  • Body weight of <43 kg (105.8 lbs) at screening.
  • History of GI bleeding or peptic ulcer disease.
  • Known active inflammatory bowel disease, e.g., Crohn's Disease or ulcerative colitis.
  • A history of bleeding disorders that may affect coagulation.
  • Subjects with prior stroke or transient ischemic attack in the past 12 months prior to screening.

Treatment and study plan

MR-107A-02

Drug

tablet

Tramadol

Drug

over-encapsulated tablet

Placebo

Drug

over-encapsulated tablet and/or tablet

Herniorrhaphy

Procedure

Unilateral open inguinal herniorrhaphy with mesh under general anesthesia

Primary outcomes

  1. Summed Pain Intensity Difference (SPID) for MR-107A-02 versus placebo.

    Time frame: 48 hours after randomization

    SPID based on a 0 to 10-point numeric rating scale with activity (NRS-A) for MR-107A-02 versus placebo.

Secondary outcomes

  1. Number of doses of opioid rescue medication taken for MR-107A-02 versus placebo.

    Time frame: 7 days after randomization

    Number of doses of opioid rescue medication over the combined in-patient and outpatient treatment phases MR-107A-02 versus placebo.

  2. Proportion of subjects using no opioid rescue medication MR-107A-02 versus placebo.

    Time frame: 7 days after randomization

    Proportion of subjects using no opioid rescue medication over the combined in-patient and outpatient treatment phases MR-107A-02 versus placebo.

  3. Summed Pain Intensity Difference (SPID) for tramadol versus placebo.

    Time frame: 7 days after randomization

    SPID based on a 0 to 10-point numeric rating scale with activity (NRS-A) for tramadol versus placebo.

  4. Summed Pain Intensity Difference (SPID) for MR-107A-02 versus tramadol

    Time frame: 48 hours after randomization

    SPID based on a 0 to 10-point numeric rating scale with activity (NRS-A) for MR-107A-02 versus tramadol.

Sponsors and collaborators

Lead sponsor

Viatris Specialty LLC

Industry

Collaborators

  • Mylan Specialty, LP

Registry information

Official study title

Multi-Center, Randomized, Double-Blind, Placebo (Double-Dummy) and Active-Controlled, Parallel-Group Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Herniorrhaphy

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Jan 22, 2024
Registry last updated
Feb 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.